CDXS
Codexis, Inc.
CDXS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
CDXS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CDXS's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
CDXS PE Valuation
CDXS has no meaningful PE right now: it lost money over the past year.
CDXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CDXS's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
CDXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.18 | +$0.57 |
| Q2 2026 | -$0.32 | +$0.50 |
| Q1 2026 | -$0.35 | +$0.63 |
| Q4 2025 | -$0.50 | +$0.39 |
| Q3 2025 | -$0.75 | +$0.13 |
| Q2 2025 | -$0.82 | +$0.27 |
| Q1 2025 | -$0.98 | -$0.04 |
| Q4 2024 | -$0.89 | +$0.23 |
CDXS is still losing money, but far less than before: $0.18 per share over the past year, against $1.20 at its worst in late 2023.
CDXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.3M | +124% |
| Q2 2026 | $14.9M | -2.7% |
| Q1 2026 | $15.2M | +102% |
| Q4 2025 | $38.9M | +81% |
| Q3 2025 | $8.6M | -33% |
| Q2 2025 | $15.3M | +92% |
| Q1 2025 | $7.5M | -56% |
| Q4 2024 | $21.5M | -19% |
CDXS's revenue is growing: $19M last quarter, up 124% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -39% | +182 points |
| Q2 2026 | -75% | +8.6 points |
| Q1 2026 | -53% | +219 points |
| Q4 2025 | 27% | +61 points |
| Q3 2025 | -220% | -91 points |
| Q2 2025 | -84% | +201 points |
| Q1 2025 | -272% | -202 points |
| Q4 2024 | -34% | -35 points |
CDXS's operating margin was −39% last quarter, up 182 points from the same quarter a year ago.
CDXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.8M | +$40K |
| Q2 2026 | -$10.5M | +$9.9M |
| Q1 2026 | -$13.3M | +$1.7M |
| Q4 2025 | $19.6M | +$37.8M |
| Q3 2025 | -$7.9M | +$6.1M |
| Q2 2025 | -$20.5M | -$7.9M |
| Q1 2025 | -$15.1M | -$6.1M |
| Q4 2024 | -$18.2M | -$7.6M |
CDXS has burned cash in almost every quarter: −$12M over the past year, against −$62M the year before.
CDXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +18% | +16.2M shares |
| 1 year | +19% | +17M shares |
| 3 years | +54% | +37.8M shares |
| 5 years | +58% | +39.5M shares |
| Available history | +90% | +50.7M shares |
CDXS has 107M diluted shares, up 19% from a year ago.
CDXS Net Leverage
CDXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CDXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.5 | Neutral |
| Stochastic | 7.2 | Oversold |
CDXS's weekly RSI is 30 (neutral) and its Stochastic is 7 (oversold).
CDXS PE vs Healthcare Sector
CDXS has no meaningful PE right now: it lost money over the past year.
CDXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.23 | 22% below |
| 20 week MA | $1.52 | 37% below |
| 50 week MA | $1.76 | 45% below |
| 100 week MA | $2.35 | 59% below |
| 200 week MA | $2.79 | 66% below |
CDXS is in a downtrend: it's below all five of its weekly moving averages, and 66% below its 200-week average.
CDXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.1 | $22.7 | +33% |
| 2021 | $22.7 | $33.4 | +47% |
| 2022 | $33.4 | $4.43 | -87% |
| 2023 | $4.43 | $3.05 | -31% |
| 2024 | $3.05 | $4.99 | +64% |
| 2025 | $4.99 | $1.63 | -67% |
| 2026 YTD | $1.63 | $0.96 | -41% |
CDXS has finished lower in three of the last six years. It's down 41% so far in 2026.